VP, Investor Relations. Kurt Bonner. Manager, Investor Relations. Lori Ursomarso. Investor Relations. +1.302.773.2263 investor@chemours.com.
Missing: ccxi | Show results with:ccxi
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered ...
Mar 1, 2022 · An investment in us is subject to a number of risks, including risks related to our financial position and capital requirements, risks related ...
ChemoCentryx Inc - Company Profile and News - Bloomberg Markets
www.bloomberg.com › profile › CCXI:US
Company profile page for ChemoCentryx Inc including stock price, company news, executives, board members, and contact information. ... Senior VP:Investor ...
Aug 4, 2022 · Investors of ChemoCentryx are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when ...
... CCXI / ChemoCentryx Inc - SEC Filings, Annual ... investor presentations (found in 8Ks), insider trades (form ... Quarterly and Annual Reports. 2022-08-08, 10-Q ...
Jun 20, 2019 · Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
Missing: relations | Show results with:relations
Title of each class. Trading Symbol(s). Name of each exchange on which registered ; Common Stock, par value $0.001 per share. CCXI. The Nasdaq Stock Market LLC ...
Missing: relations | Show results with:relations
CCXI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ChemoCentryx, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm.
People also ask
What is the second quarter earnings of the Chemours?
What is the annual revenue of Chemours?
Who are the external auditors of Chemours?
ChemoCentryx Inc (US:CCXI) has 3 institutional owners and shareholders ... Investor, Type, Avg Price (Est), Shares, Δ ... relation to any financial matter you ...